Because of the significant use of immune checkpoint inhibitors for the treatment of ccRCC patients, we investigated whether modulation of Axl, PD-L1 and MAPK/HSP27 may affect the response of sunitinib-resistant ccRCC cell lines to PD-L1 blocking therapeutic antibodies. Here, AXL is linked to nonpapillary renal cell carcinoma.